Table 1—

Predicted probabilities and risk differences between men and women for selected treatments and processes of diabetes care received during a 12-month period: the TRIAD study, 2000–2001

With CVD
Without CVD
Predicted probability
Risk difference (%)95% CIPredicted probability
Risk difference (%)95% CI
Men (%)Women (%)Men (%)Women (%)
Aspirin used39.033.25.82.1–9.416.414.02.40.4–4.4
Aspirin advised in those not using aspirin58.155.23.0−2.0 to 8.032.527.05.52.6–8.3
Lipid medications used57.651.56.12.3–9.935.934.81.1−1.4 to 3.6
Lipid profile tested in those not using lipid medications54.853.21.6−4.2 to 7.458.354.43.90.5–7.3
Antihypertensive medications used86.286.4−0.2−2.7 to 2.366.972.0−5.1−7.6 to −2.6
Urine microalbumin/protein tested in those not using antihypertensive medications43.040.12.9−6.8 to 12.632.334.9−2.6−7.2 to 1.9
HbA1c tested83.881.22.6−0.5 to 5.781.882.5−0.7−2.9 to 1.5
  • Data are generated from hierarchical logistic regression model accounting for clustering within health plan and adjusted for the proportion of men in the health plans. CVD history defined by self-reported myocardial infarction, stroke, coronary artery bypass, or angioplasty.